Aciclovir treatment for human immunodeficiency virus-1: is the “juice worth the squeeze?”

Sex Transm Dis. 2011 May;38(5):410-2. doi: 10.1097/olq.0b013e318214b6e1.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Acyclovir / administration & dosage
  • Acyclovir / economics
  • Acyclovir / therapeutic use*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / economics
  • Antiviral Agents / therapeutic use*
  • Clinical Trials as Topic
  • Coinfection / drug therapy
  • Coinfection / epidemiology
  • Cost-Benefit Analysis
  • Disease Progression
  • Female
  • HIV Infections / complications
  • HIV Infections / physiopathology
  • HIV Infections / prevention & control*
  • Herpes Genitalis / complications
  • Herpes Genitalis / drug therapy*
  • Herpes Genitalis / epidemiology
  • Herpesvirus 2, Human / drug effects*
  • Humans
  • Male
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Acyclovir